PCSK9 Inhibitor

All categories
DBCAT003524Therapeutic category

Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol... A DrugBank category of 5 drugs. 5 of them are approved.

Also known as
PCSK9 Inhibitors
Drugs

What you can answer from here — as of February 23, 2018

5DrugsEach linked to its full drug card
Listed above
1Drug targetEvery drug–target pair in the class, with bond type
Sign in
134Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
2Routes of administrationHow the drugs in this class are given
Sign in

Which targets do PCSK9 Inhibitor share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In